Atelvia is indicated for the treatment of osteoporosis in postmenopausal women. In 
postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral 
fractures and a composite endpoint of nonvertebral osteoporosis-related fractures
The optimal duration of use has not been determined. The safety and effectiveness of Atelvia for 
the treatment of osteoporosis are based on clinical data of one year duration. All patients on 
bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic 
basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 
years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated 
periodically.